Cargando…
Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study
PURPOSE: Hyperkalemia, defined as abnormally high serum potassium levels of ≥5.1 mmol/L, is associated with increased medical costs. This real-world study evaluated the impact of long-term sodium zirconium cyclosilicate (SZC) therapy on medical costs in patients with hyperkalemia. PATIENTS AND METHO...
Autores principales: | Agiro, Abiy, Dwyer, Jamie P, Oluwatosin, Yemisi, Desai, Pooja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519215/ https://www.ncbi.nlm.nih.gov/pubmed/37753303 http://dx.doi.org/10.2147/CEOR.S420217 |
Ejemplares similares
-
Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study
por: Dwyer, Jamie P., et al.
Publicado: (2023) -
Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study
por: Agiro, Abiy, et al.
Publicado: (2023) -
Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021) -
Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe Hyperkalemia
por: Ford, Martin, et al.
Publicado: (2021) -
Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021)